Wadsworth Samuel C. 4
4 · Dimension Therapeutics, Inc. · Filed Nov 7, 2017
Insider Transaction Report
Form 4
Wadsworth Samuel C.
Chief Scientific Officer
Transactions
- Disposition to Issuer
Common Stock
2017-11-07−278,035→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2017-11-07−50,000→ 0 totalExercise: $7.14Exp: 2026-01-31→ Common Stock (50,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2017-11-07−60,000→ 0 totalExercise: $1.90Exp: 2027-01-31→ Common Stock (60,000 underlying)
Footnotes (3)
- [F1]Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx, in exchange for a cash payment of $6.00 per share.
- [F2]This stock option, which vests in equal monthly installments over 48 months beginning January 27, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
- [F3]This stock option, which vests in equal monthly installments over 48 months beginning January 18, 2017, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.